This report provides exclusive insights into the COVID-19 impact on the Childhood Absence Epilepsy Treatment Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Childhood Absence Epilepsy Treatment Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Childhood Absence Epilepsy Treatment Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
report published by Infinium Global Research on childhood absence epilepsy
treatment market provides in-depth analysis of segments and sub-segments in the
global as well as regional childhood absence epilepsy treatment market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional childhood absence epilepsy treatment market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecast and dollar values of global childhood absence epilepsy
treatment market. According to the report, the global childhood absence
epilepsy treatment market is projected to grow at a CAGR of 5.1% over the
forecast period of 2019-2025.
absence epilepsy (CAE) is a common type of problem in childhood and
adolescence. It is caused by several different factors that impact the
functioning of the brain. The general causes of epilepsy are a genetic problem
or acquired or sometimes both are responsible for it. The causes of childhood
absence epilepsy change as per the age of the disease grow in the person. The
patients suffering from this type of problem suffer from the absence seizure.
The absence seizure is a condition in which a person appears as staring at
someone or something, but in reality s/he does not aware/responsive to that
situation. Further, the patient eye rolls up suddenly or eye blinks. some
patients start mouth chewing during this situation. This influence of seizure
lasts for the 10 seconds after this patient resumes his normal activities.
generally two types of seizure atypical absence seizure and typical absence
seizure. The atypical absence seizure often occurs with other types of seizure.
Further, this mainly occurs to those children, who are suffering from
neurologic disabilities. The typical
absence seizure is short duration epileptic seizure i.e. sudden start and
termination of the disease. This disease is a cluster of clinico-EEG
manifestations, which would be syndrome related. It is a pharmacologically
unique disease compared to other types of seizure problem.
As per the
Epilepsy Foundation Michigan, the epilepsy is the fourth most common
neurological disorder in the United States after migraine, stroke, and
Alzheimer’s disease. About 1.2% of Americans have some form of epilepsy, and
nearly four percent (1 in 26) population are expected to develop epilepsy at
some point in their lives. The number of Americans who have epilepsy is greater
than the number who have multiple sclerosis, Parkinson’s disease, and cerebral
palsy combined. Further, 10% of Americans are estimated to have at least one
seizure at some point in their lives. Moreover, the epilepsy is prevalent among
other disability groups in the U.S, such as autism (25.5%), cerebral palsy
(13%), Down syndrome (13.6%), and intellectual disability (25.5%). For people
with both cerebral palsy and intellectual disability, the prevalence of
epilepsy is 40%.
As per the
Morbidity and Mortality Weekly Report, August 2017, approximately 3 million
adults and 4,70,000 children had active epilepsy problem in 2015. Around 1.2%
of the U.S. population is suffering from the epilepsy problem. It estimated
that the number of patients suffering from active epilepsy problem is
increasing every year in the United States, owing to the population growth. The
estimated number of patients suffering from active epilepsy in the United
States range from 5,900 in Wyoming to 427,700 in California. Further, as per
the Centers for Disease Control and Prevention, U.S. the number of patients
with active epilepsy rose from 2.3 million in 2010 to 3 million in 2015.
Additionally, the number of children with the condition increased from 450,000
in 2007 to 470,000 in 2015.
America is the leading market of the childhood absence epilepsy treatment
market, owing to growing awareness among the parents, and governmental support
to provide long treatment through government funded healthcare scheme. Additionally, the continuous growing
population and the presence of leading medical pharmaceutical companies in this
region are boosting the growth of childhood absence epilepsy treatment market.
The report on
global childhood absence epilepsy treatment market covers segments such as
drug, and disease type. On the basis of drug, the sub-markets include
valproate, ethosuximide, lamotrigine, and phase 2 drugs (CX-8998 and
cannabidiol oral solution). On the basis of disease type, the sub-markets
include atypical absence seizures and typical absence seizures.
provides profiles of the companies in the market such as Teva Pharmaceutical
Industries Ltd., AbbVie, Insys Therapeutics, GlaxoSmithKline plc, Pfizer Inc.
and Cavion, Inc.
provides deep insights into the demand forecasts, market trends, and micro and
macro indicators. In addition, this report provides insights into the factors
that are driving and restraining the growth in this market. Moreover, The
IGR-Growth Matrix analysis given in the report brings an insight into the
investment areas that existing or new market players can consider. The report
provides insights into the market using analytical tools such as Porter's five
forces analysis and DRO analysis of childhood absence epilepsy treatment
market. Moreover, the study highlights current market trends and provides
forecast from 2019-2025. We also have highlighted future trends in the market
that will affect the demand during the forecast period. Moreover, the competitive
analysis given in each regional market brings an insight into the market share
of the leading players.